Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A specific immune signature for predicting the prognosis of glioma patients with IDH1-mutation and guiding immune checkpoint blockade therapy.

Frontiers in immunology - 1 Jan 2022

Zeng Zhirui, Hu Chujiao, Ruan Wanyuan, Zhang Jinjuan, Lei Shan, Yang Yushi, Peng Pailan, Pan Feng, Chen Tengxiang

Abstract excerpt

Isocitrate dehydrogenase (IDH1) is frequently mutated in glioma tissues, and this mutation mediates specific tumor-promoting mechanisms in glioma cells. We aimed to identify specific immune biomarkers for IDH1-mutation (IDH1mt) glioma. The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) were used to obtain RNA sequencing data and clinical characteristics of glioma tissues, while the stromal and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gene Expression Regulation, Neoplastic
Share to Glioma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Isocitrate Dehydrogenase

Share to Mutation

Share to Prognosis

Source

Open in PubMed Open full text

Identifiers

PMID: 36159801
DOI: 10.3389/fimmu.2022.1001381
PMCID: PMC9500319

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A specific immune signature for predicting the prognosis of glioma patients with IDH1-mutation and guiding immune checkpoint blockade therapy.PMID 36159801Read ↗

Development and Validation of an IDH1-Associated Immune Prognostic Signature for Diffuse Lower-Grade GliomaSemantic proximity Read ↗

Comprehensive analysis of m6A/m5C/m1A-related gene expression, immune infiltration, and sensitivity of antineoplastic drugs in gliomaSemantic proximity Read ↗

An Immune-Related Signature for Predicting the Prognosis of Lower-Grade GliomasSemantic proximity Read ↗

Association of IDH mutation and 1p19q co-deletion with tumor immune microenvironment in lower-grade gliomaSemantic proximity Read ↗

Molecular and clinical characterization of IDH associated immune signature in lower-grade gliomasSemantic proximity Read ↗

Identification Of Immune Networks Influenced By Mir-200c In IDH1-Mutant Lower-Grade Gliomas Using WGCNASemantic proximity Read ↗

Development and Validation of a Novel Prognostic Model for Glioma Based on Immune-Related GenesSemantic proximity Read ↗

Potential of IDH mutations as immunotherapeutic targets in gliomas: a review and meta-analysis.Semantic proximity Read ↗

Predictive Panel for Immunotherapy in Low-Grade Glioma.Semantic proximity Read ↗

Development of a prognostic model of glioma based on immune‑related genesSemantic proximity Read ↗

Comprehensive Molecular Analyses of a Novel Mutational Signature Classification System with Regard to Prognosis, Genomic Alterations, and Immune Landscape in GliomaSemantic proximity Read ↗

Recognition of Tumor-Associated Antigens and Immune Subtypes in Glioma for mRNA Vaccine Development.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.